BenevolentAI
subject to positive date the asset will then be ready for phase i studies in poised for growth multiple value in points ben data expected ben out licensing internal pipeline depth and progression ben begin phase i study ben submit clinical trial application expect to add names drug programmes to portfolio ben phase i data package phase to follow shortly after ben initiate phase i study collaboration other platform collaborations aim to progress stage drug candidates every year potential new targets added for and heart failure prior targets for and for advancing discussions with a number of parties ongoing inflection | BenevolentAI
Company
Deck Type
Deck date
March 2023
Slide
28 of 38
Similar slides by BenevolentAI
Investor Conference
January 2023
Investor Conference
November 2022
Investor Presentation
October 2022
Investor Day
September 2022
Related slides by other companies
Investor Presentation
May 2022
Investor Conference
May 2023
Investor Day
September 2022
Investor Presentation
January 2024
Other recent decks by BenevolentAI
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Investor Conference
January 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io